News
Featured
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed that of all previous years. The WGND is tracking 19 drug candidates that have initiated or completed a Phase 1 clinical trial for use in treating Tuberculosis. Most have been or are currently being evaluated in a Phase 2 clinical trial and one has made it to Phase 3. These 19 do...
News
6 Sep 2010
The following is a guest posting from Joanna Breitstein of the TB Alliance, reporting from the Open Forum 4 in Addis Ababa, Ethiopia. Open Forum 4 While there were few new TB treatment prospects a few years ago, today there are 10 drugs in the global development pipeline. Noting the sea of change,...
2 Sep 2010
This is part three of our interview, which was recorded on June 9, 2010 at the Global Tuberculosis Institute in Newark, NJ. > click here to view part one . >click here to view part two Dr. Lee Reichman Lee B. Reichman, MD, MPH, is the Founding Executive Director of the New Jersey Medical...
25 Aug 2010
This is part two of our interview, which was recorded on June 9, 2010 at the Global Tuberculosis Institute in Newark, NJ. > click here to view part one . Dr. Lee Reichman Lee B. Reichman, MD, MPH, is the Founding Executive Director of the New Jersey Medical School Global Tuberculosis Institute,...
24 Aug 2010
A distinct whole-blood 86-gene transcriptional signature of active TB (Figure 2 in the paper) Last week, a paper was published in Nature by Matthew Berry, Christine Graham et al. which received a fair amount of notice. The authors presented data identifying a probable TB gene signature in people...
19 Aug 2010
This story originally appeared on Reuters here: http://www.reuters.com/article/idUSTRE67H3OH20100818 A patient who tested positive for extreme drug resistant tuberculosis (XDR-TB) awaits treatment at a rural hospital at Tugela Ferry in South Africa's impoverished KwaZulu Natal province, in this...
18 Aug 2010
Working Group on New TB Drugs Annual Meeting SAVE THE DATE: November 12, 2010 WGND Annual Meeting in Berlin The WGND will host our annual meeting prior to the start of the IUATLD meeting in Berlin. WHEN: Friday, November 12, 2010, 9am-12pm WHERE: The Kempinski Hotel Bristol Berlin, http://www...
18 Aug 2010
Cameron Kaiser, MD Last week , Dr. Kaiser shared his thoughts and perspectives as a medical doctor on the current state of TB drug regimens. This week he shares specific ideas on how TB drug R&D could be improved. From a clinical perspective, I think there are some less obvious aims to optimize...
16 Aug 2010
Review of JACS Communication, “Catalytic Asymmetric Synthesis of R207910″ By Christopher Cooper, Director of Chemistry, TB Alliance Retrosynthetic Approach to TMC207 (click to view larger) The novel antitubercular agent TMC207 ( Tibotec , a Johnson & Johnson company) represents an impressive...
16 Aug 2010
This article originally appeared on Citizen News Service. Click here to read the original post. by Shobha Shukla Open Forum 4 The Open Forum 4 on key issues in tuberculosis (TB) drug development is all set to begin in Addis Ababa, Ethiopia (18-19 August 2010). This Open Forum 4, will raise and...
16 Aug 2010
This post originally appeared on Citizen News Service. Click here to view the post. By Masimba Biriwasha, CNS Art by Beatien Yazz at http://bit.ly/b28RCZ TUBERCULOSIS (TB) has a major impact on women’s sexual reproductive health and that of their children. For pregnant women living in areas with...
11 Aug 2010
Cameron Kaiser, MD Viewpoint by Cameron Kaiser, MD, Medical Consultant for Tuberculosis, Riverside County Department of Public Health, California and guest WGND blogger. Antibiotics are, to the typical patient, always the quick fix. Despite our best attempts to convince them that their viral...
10 Aug 2010
2.1 Å DNA gyrase complex with GSK299423 (Figure 2 from paper) This week we reposted an article from DailyFinance.com regarding a new antibactierial compound from GlaxoSmithKline (GSK) . GSK has recently published a Nature paper describing the 2.1 angstom crystal structure of Staphylococcus aureus...
8 Aug 2010
Originally posted on DailyFinance: http://srph.it/d7qPd8 . AOL Daily Finance GlaxoSmithKline ( GSK ) researchers announced Wednesday that they have found a new compound that may help in the fight against drug-resistant bacteria. The findings could ultimately assist scientists in developing new...
4 Aug 2010
TB Misdiagnosis: Swedish Student Compelled to Take TB Drugs for a Year This is the first in our series “TB Treatment Stories,” where we meet people who have had first-hand experience taking standard tuberculosis drugs, which were developed and approved more than 40 years ago . As the Working Group...
3 Aug 2010
Cofactor F420 Structure The need for the identification of novel TB drug targets and biomarkers has been highlighted in a few of our posts over the last several months. A recent epublication (online manuscript before print) in the Journal of Bacteriology by Jeremy D. Selengut and Daniel H. Haft...
